Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Cabometyx

    - PMLiVE

    Ipsen to acquire ImCheck Therapeutics in a deal worth up to €1bn

    The acquisition includes a clinical stage acute myeloid leukaemia treatment currently in phase 1/2 trials

    - PMLiVE

    Ipsen’s tumour treatment receives MHRA marketing authorisation

    This is the first approval in the UK for previously treated advanced neuroendocrine tumours

    - PMLiVE

    Ipsen receives EC approval for Cabometyx in advanced neuroendocrine tumours

    Treatment options following disease progression have previously been limited for many patients

    - PMLiVE

    Ipsen receives CHMP recommendation for Cabometyx in neuroendocrine tumours

    The number of patients newly diagnosed with NETs is believed to be on the rise

    - PMLiVE

    Ipsen’s elafibranor shows promise in rare liver disease primary sclerosing cholangitis

    The drug already holds approvals to treat primary biliary cholangitis, another rare liver disease

    - PMLiVE

    Ipsen’s Iqirvo accepted by SMC to treat rare liver disease primary biliary cholangitis

    The life-long condition affects approximately 1,900 people in Scotland

    - PMLiVE

    FDA approves Exelixis’ Cabometyx to treat advanced neuroendocrine tumours

    Approximately 380,000 people in the US were affected by NETs in 2024

    - PMLiVE

    Roche gains rights to Innovent Biologics’ ADC candidate in deal worth over $1bn

    IBI3009 targets an antigen significantly overexpressed in cancers including small cell lung cancer

    - PMLiVE

    Over 40 years of Ipsen in the UK: resilience and leadership in the life sciences sector

    By Ioana Parsons

    - PMLiVE

    Ipsen enters $610m licensing deal with Biomunex to advance MAIT-cell engager

    The candidate targets a tumour antigen that is highly expressed across several cancer types

    - PMLiVE

    Ipsen shares positive three-year results for Iqirvo in primary biliary cholangitis

    The rare liver disease affects approximately 100,000 people in the US

    - PMLiVE

    Ipsen’s Iqirvo recommended by NICE to treat rare liver disease primary biliary cholangitis

    The disease affects approximately 25,000 people in the UK, the majority of whom are women

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links